GHGuido Hansen

Guido Hansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guido Hansen has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Thomas Krey

    Center of Structural and Cell Biology in Medicine, Institute of Biochemistry, University of Luebeck, Luebeck, Germany

    3 shared publications
  • Britta Schwarzloh

    Institute of Biochemistry, Center of Structural and Cell Biology in Medicine, University of Lübeck

    2 shared publications
  • Doris Mutschall

    Institute of Biochemistry, Center of Structural and Cell Biology in Medicine, University of Lübeck

    2 shared publications
  • Elisabeth Herold

    Institute of Biochemistry, Center of Structural and Cell Biology in Medicine, University of Lübeck

    2 shared publications
  • Florian Klein

    Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne

    2 shared publications
  • Hannah Kleine-Weber

    Faculty of Biology and Psychology, German Primate Center, Leibniz Institute for Primate Research, University of Göttingen

    2 shared publications

Latest Publications

  • Open Access

    Structural basis of porcine reproductive and respiratory syndrome virus 2 neutralization by a GP4-targeting monoclonal antibody

    by Barbora Veselkova, Chandamita Saikia, Sebastian Affeldt, Sandra Barth, Manoj Kumar Rajak, Frithjof Besa, Daria Bezbakh, Guido Hansen, Till Rümenapf, Matthias Ballmaier, et al.

    Porcine reproductive and respiratory syndrome virus (PRRSV) is a genetically diverse RNA virus that causes reproductive failure and respiratory disease in pigs, leading to major economic losses worldwide. Although inactivated and live-attenuated vaccines are available, they provide only partial protection, allowing endemic circulation, persistent transmission and recurrent outbreaks. The limited efficacy of current vaccines reflects the incomplete understanding of immune correlates of protection. Here, we describe a murine monoclonal antibody (IgG #18) with potent, strain-specific neutralizing activity against PRRSV-2. Epitope mapping localized its binding site to the N-terminal region of the minor glycoprotein GP4. Functional and biochemical analyses demonstrated high-affinity binding and effective neutralization, while crystallographic studies revealed its atomic structure in complex with an epitope peptide. To our knowledge, this structure provides the first structural snapshot of a neutralization epitope within the PRRSV glycoproteins, providing insights into the conformation of this key component of the PRRSV envelope complex. This structure also explains the restricted specificity of IgG #18, highlighting the challenge of epitope variability across PRRSV species. Our findings advance understanding of antibody-mediated neutralization and provide an initial framework for the use of structural information in the design of next-generation immunogens aimed at eliciting protective responses against genetically diverse PRRSV strains.


  • Open Access

    A critical residue in a conserved RBD epitope determines neutralization breadth of pan-sarbecovirus antibodies with recurring YYDRxxG motifs

    by Saskia C. Stein, George Ssebyatika, Tim Benecke, Luisa Ströh, Manoj K. Rajak, Benjamin Vollmer, Sarah Menz, Ja-Yun Waldmann, Sarah N. Tipp, Okechukwu Ochulor, et al.

    The emergence of pandemic coronaviruses remains a global health concern, highlighting the need for broadly neutralizing antibodies (bnAbs) that can target multiple sarbecoviruses. In this study, we isolated and characterized a novel antibody, pT1679, that demonstrates exceptional neutralization breadth. The antibody prevented infection with SARS-CoV-2 variants of concern, such as Omicron BA.1, and effectively neutralized pseudotyped viruses displaying S proteins from many SARS-CoV-2 variants and various bat and pangolin sarbecoviruses, including both SARS-CoV-like and SARS-CoV-2-like viruses. In addition, pT1679 reduced the viral load in the lung of infected Syrian hamsters and prevented the severe lung pathology typical for SARS-CoV-2 infections. The cryo-electron microscopy structure of pT1679 in complex with SARS-CoV-2 S revealed that the antibody employs a YYDRxxG motif to recognize a highly conserved epitope on the RBD. Through detailed structural analysis, mutagenesis studies, and binding assays, we identified RBD residue 384 as a critical determinant of antibody recognition. Structure-function analyses of several related bnAbs, such as COVA1-16, allowed for the classification of YYDRxxG antibodies into two distinct groups that differ in neutralization breadth. Our findings provide crucial insights into the molecular basis of broad Sarbecovirus neutralization and offer strategic guidance for selecting therapeutic antibodies in preparation for future Sarbecovirus outbreaks. IMPORTANCE: The threat of emerging coronaviruses demands therapeutic strategies capable of targeting both current and future circulating viruses. We report the discovery and characterization of pT1679, a broadly neutralizing antibody that demonstrates cross-reactivity against diverse sarbecoviruses, including SARS-CoV, SARS-CoV-2 variants, and related viruses from bats and pangolins. pT1679 targets a highly conserved epitope via a YYDRxxG motif in the paratope, with RBD residue 384 serving as a critical determinant of recognition. Our analysis allows for a classification of YYDRxxG antibodies, providing a framework for predicting antibody effectiveness against emerging sarbecoviruses.


  • Open Access

    A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation

    by Saskia C. Stein, Guido Hansen, George Ssebyatika, Luisa J. Ströh, Okechukwu Ochulor, Elisabeth Herold, Britta Schwarzloh, Doris Mutschall, Jasmin Zischke, Anne K. Cordes, et al.

    The effectiveness of SARS-CoV-2 therapeutic antibodies targeting the spike (S) receptor-binding domain (RBD) has been hampered by the emergence of variants of concern (VOCs), which have acquired mutations to escape neutralizing antibodies (nAbs). These mutations are not evenly distributed on the RBD surface but cluster on several distinct surfaces, suggesting an influence of the targeted epitope on the capacity to neutralize a broad range of VOCs. Here, we identified a potent nAb from convalescent patients targeting the receptor-binding domain of a broad range of SARS-CoV-2 VOCs. Except for the Lambda and BA.2.86 variants, this nAb efficiently inhibited the entry of most tested VOCs, including Omicron subvariants BA.1, BA.2, XBB.1.5, and EG.5.1 and to a limited extent also BA.4/5, BA.4.6, and BQ.1.1. It bound recombinant S protein with picomolar affinity, reduced the viral load in the lung of infected hamsters, and prevented the severe lung pathology typical for SARS-CoV-2 infections. An X-ray structure of the nAb-RBD complex revealed an epitope that does not fall into any of the conventional classes and provided insights into its broad neutralization properties. Our findings highlight a conserved epitope within the SARS-CoV-2 RBD that should be preferably targeted by therapeutic antibodies and inform rational vaccine development. IMPORTANCE: Therapeutic antibodies are effective in preventing severe disease from SARS-CoV-2 infection and constitute an important option in pandemic preparedness, but mutations within the S protein of virus variants (e.g., a mutation of L452) confer resistance to many of such antibodies. Here, we identify a human antibody targeting the S protein receptor-binding domain (RBD) with an elevated escape barrier and characterize its interaction with the RBD functionally and structurally at the atomic level. A direct comparison with reported antibodies targeting the same epitope illustrates important differences in the interface, providing insights into the breadth of antibody binding. These findings highlight the relevance of an extended neutralization profiling in combination with biochemical and structural characterization of the antibody-RBD interaction for the selection of future therapeutic antibodies, which may accelerate the control of potential future pandemics.


  • Inhibitory effect of sorangicin A against mutant DNA-dependent RNA polymerase in the obligate intracellular bacterium Chlamydia trachomatis

    by Qiang Li, Hendrik Jansen, Guido Hansen, Dennis Nurjadi, Jennifer Herrmann, Marc Stadler, Mark Brönstrup, Rolf Müller, Cheng He, Simon Graspeuntner, et al.